NEW YORK (GenomeWeb News) – Genomic Health reported after the close of the market Tuesday that its second-quarter revenues increased 32 percent on increased sales of its Oncotype Dx breast cancer test.

The Redwood City, Calif.-based pharmacogenomic test developer and service provider brought in total revenues of $36.6 million, up from $27.8 million for the second quarter of 2008. Product revenue from Oncotype Dx was $35.2 million, an increase of 34 percent over revenue of $26.3 million for the comparable period of 2008.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The president of France's National Research Agency has resigned, according to Nature News.

A senator wants a "right-to-try" provision in the US Food and Drug Administration funding bill, but an ethicist says at Stat News that it would undermine the role of clinical trials.

In PNAS this week: red algae Porphyra umbicalis genome, deep neural network model for sequencing peptides, and more.

The Guardian's Barbara Ellen has tried out some DNA testing services to see whether they provide valuable information.